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Introduction
The ongoing coronavirus 2019 (COVID-19) was 
initially reported from Wuhan, China, in December 
2019. After few weeks, it has been involved in several 
countries and became a significant global public 
health problem  [1-3]. World Health Organization 
(WHO) designated COVID-19 as a pandemic disease 
on March 11, 2020 (WHO, situational Report-52). 
The most known symptoms of COVID-19 are fever, 
cough, shortness of breathing, and occasional watery 
diarrhea [4]. Even though COVID-19 often causes mild 
symptoms compared to other respiratory infections, it 
can cause severe illness in certain groups of people, such 
as the elderly and people with major underlying health 
problems (cardiovascular disease and diabetes) [5].
There are two key parameters to understand the 
epidemiological features of an outbreak or epidemic. 
These are primary reproduction numbers (R0) and case-
fatality rates (CFR) [6, 7]. The R0 is an epidemiologic 
metric that has been used to assess the infectiveness of 
the agents that cause an outbreak. This index explains the 
average number of new cases generated from an infected 
person. The higher amount of R0 indicates the highest 
transmissibility of the infection agent. An estimated 
R0 of the COVID-19 virus is 3.32, which means one 
infected case can transmit the virus to 3 to 4  susceptible 
individuals [8]. CFR is another essential index that helps 
to understand the epidemiological characteristics of 
an outbreak. The CFR of COVID-19 is defined as the 
number of deaths in COVID-19 cases divided by the total 
number of people infected by COVID-19 [9]. Previously 
reported CFR of COVID-19 is highly variable. The 
primary cause of this heterogeneity could be varied as 
a result of surveillance systems sensitivity. Surveillance 
system sensitivity low due to more than 80% of cases 
does not show symptoms of the disease or show mild 
symptoms. Thus, cases missed by the surveillance system 
are not considered in the denominator and could lead to 
overestimation of CFR [10, 11]. Several primary studies 
have been conducted to estimate the CFR of COVID-19 
across the world and reported extremely heterogeneous 
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magnitude. However, no review study has attempted to 
estimate pooled CRF of COVID-19 from the available 
literature to understand better the nature of an outbreak 
and the virulence of the disease. Thus, the current study 
was aimed to estimate pooled CFR of COVID-19 from 
primary studies reported from different countries using 
systematic review and meta-analysis.
Materials and methods
Search strategy 
This systematic review and meta-analysis were 
performed to estimate pooled CRF of COVID-19 
from the primary studies published in international 
electronic databases. Electronic databases: PubMed, 
Scopus, Science Direct, and Google Scholar were 
searched to retrieve eligible studies that were conducted 
to estimate CFR of COVID-19. Keywords: (“COVID-
19”OR “COVID-2019” OR “severe acute respiratory 
syndrome coronavirus 2”OR “severe acute respiratory 
syndrome coronavirus 2” OR “2019-nCoV” OR 
“SARS-CoV-2” OR “2019nCoV” OR ((“Wuhan” 
AND (“coronavirus” OR “coronavirus”)) AND 
(2019/12[PDAT] OR 2020[PDAT]))) AND (“mortality 
“OR “mortality” OR (“case” AND “fatality” AND 
“rate”) OR “case fatality rate”) were used in free text 
and MeSH terms. 
Study selection and data extraction 
All studies published in 2020 and reported CFR for 
COVID-19 were included in this review (Fig. 1). From 
each included study, extracted information on the first 
author’s name, the country from where the study was 
reported, year of study, sample size, type of study, age, 
gender, comorbidity, and CFR with a 95% confidence 
interval (Tab. I and II). 
Statistical analysis 
Cochran’s Q test’s heterogeneity in the CFR of 
COVID-19 between different studies was assessed 
with a significance level of P < 0.1 and I2 statistic with 
values  >  75%  [12]. A random-effects meta-analysis 
model was used to estimate pooled CFR because 
of the presence of high heterogeneity (I2  =  99.7% 
and Cochran’s Q (p  <  0.001). The univariate meta-
regression model was used to assess the effect of 
sample size on the heterogeneity of pooled CFR. 
Publication bias was evaluated by Beggs and Eggers 
tests. Also, the risk of bias analysis performed 
using the Newcastle-Ottawa Scale for observational 
studies  [13]. Data were analyzed by STATA v 11 
(StataCorp, College Station, TX, USA). 
Fig. 1. PRISMA Flow Diagram for included studies in the current meta-analysis.
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Results
Figure 1 depicts the study selection procedure. A total of 516  
records were retrieved through electronic databases search, 
and 324 identified articles after removing 192 pieces due 
to duplication and irrelevance for the review purpose. The 
second stape 236 articles were excluded after the title and 
abstract screeded for the inclusion and exclusion criteria. Of 
the remaining 88 articles, 49 articles were excluded due to a 
lack of relevant information or not original articles. Finally, 
39 articles reported CFR of COVID-19 were included in 
the final analysis (Fig. 1 and Table 1).
The Median and IQR( Interquartile range) of reported CFR 
rate were 8.7%(23.0-1.0). The Minimum and Maximum 
reported CFR were 0 and 70.6% respectivly (Fig. 2). The 
overall pooled estimated CFR of COVID-19 was 10.0% 
(95% CI: 8.0-11.0; P < 0.001, I2 = 99.7) (Fig. 2). The pooled 
estimated CFR of COVID-19 among general population 
was 1.0% (95% CI: 1.0-3.0; P < 0.001, I2 = 94.3), while in 
hospitalised patients 13.0% (95% CI: 9.0-17.0; P < 0.001, 
I2 = 95.6) (Fig. 2). The pooled estimated CFR of COVID-19 
in the patients admited to ICU was 37.0% (95% CI: 24.0-
51.0; P < 0.001, I2 = 97.8), and in patients younger than 
50 years 3.0% (95% CI: 0.0-6.0; P < 0.001, I2 = 99.2), while 
the CFR was 19.0% (95% CI: 13.0-24.0; P < 0.001, I2 = 99.8) 
in patients older than 50 years (Fig. 2 and Table 2). Based 
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Chen et al. 
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Ning Tang et al. 
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Morteza 
Abdullatif 
Khafaie et al. 
2020 [47]
World 337570 Both Retrospective-cohort Unknown 0.0434
Huang et al. 
(2020) [48]
China 41 Both 49 Prospective Total 0.15
Huang et al. 
(2020) [48]
China 13 Both 49 Prospective ICU 0.38
Huang et al. 
(2020) [48]
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Wei-Jie Guan et 
al. (2020) [49]
China 926 Both 45 Retrospective General Population 0.001
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Nikpouraghdam 
et al. (2020) [1]
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▶
Tab. II. The estimated case fatality rate of COVID-19 in different subgroups.
Group Pooled estimation (%) 95% CI Q I2 (%)
General population 1.00 1.0-3.0 P < 0.001 94.3
Hospitalized patients 13.0 9.0-17.0 P < 0.001 95.6
ICU admitted 37.0 24.0-51.0 P < 0.001 97.8
Unknown 4.0 3.0-5.0 P < 0.001 97.8
≤ 50 3.0 0.0-6.0 P < 0.001 93.7
> 50 19.0 13.0-24.0 P < 0.001 98.1
Unknown 2.0 1.0-3.0 P < 0.001 99.8
Overall 10.0 8.0-11.0 P < 0.001 99.7
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Fig. 2. The forest plot of estimated case fatality rate of COVID-19 in different subgroups.
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on Beggs test there was no publication bias(P = 0.2), but 
the Eggers tests was shown the presence of publication bias 
(P < 0.001). Moreover, based on metaregresion regression 
analysis, ample size was not significantly associated with 
heatrogeneity of pooled estimated CFR (P = 0.31) (Fig. 3).
Discussion 
The present study systematically reviewed the available 
literature to estimate the overall pooled CFR COVID-19 
and specific subpopulations in patients admitted 
in hospital, ICU, and old. Based on 39  studies that 
fulfilled this study, the overall estimated pooled CFR 
of COVID-19 was 10.0%. The pooled CRF was only 
1.0% in the general population, while 29% in patients 
admitted in ICU and 15% in hospitalized patients. 
Although there is limited information on COVID-19 
CFR, some primary studies have been reported CFR in 
different countries with various target populations. For 
example, the studies reported from Italy have indicated 
a 9.26% CFR of COVID-19 [47, 50]. Moreover, studies 
reported from Spain and France have reported 6.16 and 
4.21% CFR, respectively [47, 50]. Furthermore, a study 
reported from Iran shown that 7.9% of CFR, while the 
study reported from Turkey indicated 2.0% CFR of 
COVD-19 [47, 50]. Compared to the previous studies 
cited above, our meta-analysis finding, based on primary 
studies reported from different countries, indicated CFR 
with a wide range. This difference between our CFR 
with its broad range and the previous study could be due 
to the target population difference.
Moreover, it might be due to case/death finding and 
reporting capacity between the countries where the 
primary studies were reported. Furthermore, case and 
death reporting in some countries might be influenced 
by political decisions. Thus, these probable reasons 
could affect the overall estimation of CFR, which could 
impact the actual epidemiological feature of the disease. 
CFR of COVID-19 ranges between 4 and 11% among 
hospitalized adult patients in different countries based 
on previous studies [51]. The present study showed 
that high (13%) CFR in hospital admitted patients. The 
present study was also revealed that CFR in patients 
admitted to ICU was 37%. In contrast to our findings, 
a case series study reported from Seattle indicated 
high CFR (50%) among critically ill patients  [32]. 
Moreover, a study reported from Washington state the 
highest CFR (67%) in patients admitted to ICU. Thus 
the health background of patients admitted to ICU could 
be an essential factor related to death [52]. For example, 
among patients admitted to ICU in Washington, 86% 
have comorbidities such as chronic kidney disease and 
congestive heart failure [52]. High CFR among patients 
admitted to ICU is mainly attributable to comorbidities 
and old age, which exacerbate the morbidity that leads 
to poor outcomes in patients admitted to ICU. Patients 
with comorbidities and old age demand great attention 
to recover from COVID-19, and more evidence requires 
better understanding to inform health care [32]. 
The present meta-analysis revealed a significant 
difference in CFR in the age group younger than 50 
years and older (3.0 vs 19%). In Italy, CFR was 52.3 in 
patients more aged than 80 years and 35.6 in 70-79 years 
old [9]. Similarly, in Chinese, CFR was high among the 
most aging patients  [53]. Besides CFR differences in 
age groups, the overall CFR reported from Italy (7.2%) 
is substantially higher than in China (2.3%) [9, 53]. 
The difference in CFR is not only related to age, rather 
other factors such as. Occupation, gender, and clinical 
Fig. 3. The beggs funnel plot to assess publication bias.
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comorbid could be contributed to high CFR in the 
old age group. A better method to preventing possible 
misconceptions about age effect on CFR in COVID-19 
patients direct age adjustment could be a solution. 
Several factors could affect on mortality of COVID-19 
in different settings due to health system capacity, age 
variation, the burden of chronic diseases, perception 
regarding COVID-19, and other unknown factors. For 
instance, the majority of COVID-19 confirmed cases in 
Italy are in old proportion. Moreover, most deaths due to 
COVID-19 in Italy are among geriatric, male patients with 
comorbidity  [9]. In addition, the number of symptoms 
the cases shown is probably affected by death due to 
COVID-19. For example, some patients have only one or 
three main symptoms of COVID-19, but some patients 
reveal more than three symptoms which most probably 
affects the death due to COVID-19. Thus, advanced, in-
depth analyses are required to explore the effect of the 
number of signs on fatalities associated with COVID-19. 
Prior findings suggested that CFR of COVID-19 seems 
to be less deadly compared to Bird flu, Ebola, SARS, 
and MERS , However, it becomes a global economic 
and public health concern  [47, 54]. In most patients, 
COVID-19 shows mild symptoms, which hid the 
burden of the disease and facilitate transmission in the 
community rapidly  [47]. Thus, media should play a 
significant role in enhancing health literacy because the 
unique characteristics of COVID-19 make the general 
community at risk. Some undetected or delayed cases 
could probably lead to underestimation of CFR of 
COVID-19. Underestimation could be linked to the level 
of the general public and politicians’ preparedness and 
mitigation.
Conclusions
The pooled estimate CFR of COVID-19 in this review is 
considerably high and differs between different patient 
groups. The CFR was higher in patients admitted in ICU 
and older than 50 years. Moreover, the present review 
results highlighted the need for transparency in testing 
and reporting policies and denominators used in CFR 
estimation. It is also necessary to report the case’s age, 
sex, and comorbidity distribution of all patients, which 
is essential in comparing the CFR among different 
population segments.
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